Treatment and prevention of herpes labialis
- PMID: 19074705
- PMCID: PMC2602638
Treatment and prevention of herpes labialis
Abstract
Objective: To review the evidence regarding the treatment and prevention of herpes labialis.
Quality of evidence: The evidence relating to treatment and prevention of herpes labialis is derived from randomized controlled trials (level I evidence).
Main message: Treatment with an indifferent cream (zinc oxide or zinc sulfate), an anesthetic cream, or an antiviral cream has a small favourable effect on the duration of symptoms, if applied promptly. This is also the case with oral antiviral medication. If antiviral medicine (cream or oral) is started before exposure to the triggering factor (sunlight), it will provide some protection. Research on sunscreens has shown mixed results: some protection has been reported under experimental conditions that could not be replicated under natural conditions. In the long term, the number of relapses of herpes labialis can be limited with oral antiviral medication.
Conclusion: Only prompt topical or oral therapy will alleviate symptoms of herpes labialis. Both topical and oral treatment can contribute to the prevention of herpes labialis.
OBJECTIF: Revoir les données concernant le traitement et la prévention de l’herpès labial.
QUALITÉ DES PREUVES: Les preuves concernant le traitement et la prévention de l’herpès labial proviennent d’essais cliniques randomisés (preuves de niveau I).
PRINCIPAL MESSAGE: Le traitement avec une crème non spécifique (oxyde ou sulfate de zinc), anesthésiante ou antivirale a un effet légèrement favorable sur la durée des symptômes à condition que la crème soit appliquée précocement. On obtient le même effet avec une médication antivirale orale. Si le traitement antiviral (en crème ou per os) est institué avant l’exposition au facteur déclenchant (lumière solaire), il conférera une certaine protection. La recherche sur les écrans solaires a donné des résultats contradictoires: dans des conditions expérimentales, on a rapporté une certaine protection mais cela n’a pu être confirmé dans des conditions naturelles. À long terme, le nombre de récidives de l’herpès labial peut être réduit par les antiviraux oraux.
CONCLUSION: Seuls un traitement topique ou une médication orale précoces peuvent soulager les symptômes de l’herpès labial. Les traitements topiques ou oraux peuvent contribuer à la prévention de l’herpès labial.
Similar articles
-
Herpes Labialis: An Update.Recent Pat Inflamm Allergy Drug Discov. 2017;11(2):107-113. doi: 10.2174/1872213X11666171003151717. Recent Pat Inflamm Allergy Drug Discov. 2017. PMID: 28971780 Review.
-
Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: a randomized, double-blind, placebo-controlled trial. Penciclovir Cream Herpes Labialis Study Group.Clin Ther. 2000 Jan;22(1):76-90. doi: 10.1016/s0149-2918(00)87979-5. Clin Ther. 2000. PMID: 10688392 Clinical Trial.
-
Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group.JAMA. 1997 May 7;277(17):1374-9. JAMA. 1997. PMID: 9134943 Clinical Trial.
-
Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced herpes labialis.Antimicrob Agents Chemother. 2002 Jun;46(6):1870-4. doi: 10.1128/AAC.46.6.1870-1874.2002. Antimicrob Agents Chemother. 2002. PMID: 12019102 Free PMC article. Clinical Trial.
-
The role of topical 5% acyclovir and 1% hydrocortisone cream (Xerese™) in the treatment of recurrent herpes simplex labialis.Postgrad Med. 2010 Sep;122(5):1-6. doi: 10.3810/pgm.2010.09.2216. Postgrad Med. 2010. PMID: 20873400 Review.
Cited by
-
Human Neural Stem Cell Systems to Explore Pathogen-Related Neurodevelopmental and Neurodegenerative Disorders.Cells. 2020 Aug 12;9(8):1893. doi: 10.3390/cells9081893. Cells. 2020. PMID: 32806773 Free PMC article. Review.
-
Oral gel loaded with penciclovir-lavender oil nanoemulsion to enhance bioavailability and alleviate pain associated with herpes labialis.Drug Deliv. 2021 Dec;28(1):1043-1054. doi: 10.1080/10717544.2021.1931561. Drug Deliv. 2021. PMID: 34060397 Free PMC article.
-
Current management and recommendations for access to antiviral therapy of herpes labialis.J Clin Virol. 2012 Jan;53(1):6-11. doi: 10.1016/j.jcv.2011.08.003. Epub 2011 Sep 1. J Clin Virol. 2012. PMID: 21889905 Free PMC article. Review.
-
Anti-herpetic Activity of Macrocystis pyrifera and Durvillaea antarctica Algae Extracts Against HSV-1 and HSV-2.Front Microbiol. 2020 Sep 11;11:2006. doi: 10.3389/fmicb.2020.02006. eCollection 2020. Front Microbiol. 2020. PMID: 33013743 Free PMC article.
-
Laser treatment of recurrent herpes labialis: a literature review.Lasers Med Sci. 2014 Jul;29(4):1517-29. doi: 10.1007/s10103-013-1311-8. Epub 2013 Apr 13. Lasers Med Sci. 2014. PMID: 23584730 Review.
References
-
- Van der Linden MW, Westert GP, De Bakker DH, Schellevis FG. Second national study into diseases and actions in general practice. Utrecht, Bilthoven: Netherlands Institute for Health Services Research (NIVEL), National Institute of Public Health and the Environment (RIVM); 2004. [Dutch]
-
- Sparano JA, Sarta C. Infection prophylaxis and antiretroviral therapy in patients with HIV infection and malignancy. Curr Opin Oncol. 1996;8(5):392–9. - PubMed
-
- Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med. 1987;316(23):1444–9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials